<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35572196</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Print">2372-7705</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>25</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
              <Day>16</Day>
            </PubDate>
          </JournalIssue>
          <Title>Molecular therapy oncolytics</Title>
          <ISOAbbreviation>Mol Ther Oncolytics</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Dependency of EGFR activation in vanadium-based sensitization to oncolytic virotherapy.</ArticleTitle>
        <Pagination>
          <StartPage>146</StartPage>
          <EndPage>159</EndPage>
          <MedlinePgn>146-159</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.omto.2022.04.004</ELocationID>
        <Abstract>
          <AbstractText>Oncolytic virotherapy is a clinically validated approach to treat cancers such as melanoma; however, tumor resistance to virus makes its efficacy variable. Compounds such as sodium orthovanadate (vanadate) can overcome viral resistance and synergize with RNA-based oncolytic viruses. In this study, we explored the basis of vanadate mode of action and identified key cellular components in vanadate's oncolytic virus-enhancing mechanism using a high-throughput kinase inhibitor screen. We found that several kinase inhibitors affecting signaling downstream of the epidermal growth factor receptor (EGFR) pathway abrogated the oncolytic virus-enhancing effects of vanadate. EGFR pathway inhibitors such as gefitinib negated vanadate-associated changes in the phosphorylation and localization of STAT1/2 as well as NF-κB signaling. Moreover, gefitinib treatment could abrogate the viral sensitizing response of vanadium compounds <i>in vivo</i>. Together, we demonstrate that EGFR signaling plays an integral role in vanadium viral sensitization and that pharmacological EGFR blockade can counteract vanadium/oncolytic virus combination therapy.</AbstractText>
          <CopyrightInformation>© 2022 The Authors.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wong</LastName>
            <ForeName>Boaz</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Centre for Innovative Cancer Research, Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, ON K1H 8L6 Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bergeron</LastName>
            <ForeName>Anabel</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Centre for Innovative Cancer Research, Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, ON K1H 8L6 Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alluqmani</LastName>
            <ForeName>Nouf</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Centre for Innovative Cancer Research, Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, ON K1H 8L6 Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Maznyi</LastName>
            <ForeName>Glib</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Centre for Innovative Cancer Research, Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, ON K1H 8L6 Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Andrew</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Centre for Innovative Cancer Research, Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, ON K1H 8L6 Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Arulanandam</LastName>
            <ForeName>Rozanne</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Centre for Innovative Cancer Research, Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, ON K1H 8L6 Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Diallo</LastName>
            <ForeName>Jean-Simon</ForeName>
            <Initials>JS</Initials>
            <AffiliationInfo>
              <Affiliation>Centre for Innovative Cancer Research, Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, ON K1H 8L6 Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>19</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Mol Ther Oncolytics</MedlineTA>
        <NlmUniqueID>101666776</NlmUniqueID>
        <ISSNLinking>2372-7705</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">EGFR</Keyword>
        <Keyword MajorTopicYN="N">cancer immunotherapy</Keyword>
        <Keyword MajorTopicYN="N">cell signaling</Keyword>
        <Keyword MajorTopicYN="N">interferon</Keyword>
        <Keyword MajorTopicYN="N">oncolytic virotherapy</Keyword>
        <Keyword MajorTopicYN="N">vanadium</Keyword>
        <Keyword MajorTopicYN="N">viral sensitization</Keyword>
      </KeywordList>
      <CoiStatement>J.S.D is co-inventor on a patent covering the use of vanadium compounds as enhancer of RNA viruses and holds shares in Virica Biotech and Virano Therapeutics that holds a license to this and related intellectual property.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>16</Day>
          <Hour>4</Hour>
          <Minute>9</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35572196</ArticleId>
        <ArticleId IdType="pmc">PMC9065483</ArticleId>
        <ArticleId IdType="doi">10.1016/j.omto.2022.04.004</ArticleId>
        <ArticleId IdType="pii">S2372-7705(22)00056-0</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Lichty B.D., Breitbach C.J., Stojdl D.F., Bell J.C. Going viral with cancer immunotherapy. Nat. Rev. Cancer. 2014;14:559–567. doi: 10.1038/nrc3770.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc3770</ArticleId>
            <ArticleId IdType="pubmed">24990523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pikor L.A., Bell J.C., Diallo J.-S. Oncolytic viruses: exploiting cancer’s deal with the devil. Trends Cancer. 2015;1:266–277. doi: 10.1016/j.trecan.2015.10.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.trecan.2015.10.004</ArticleId>
            <ArticleId IdType="pubmed">28741515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ilkow C.S., Swift S.L., Bell J.C., Diallo J.-S. From scourge to cure: tumour-selective viral pathogenesis as a new strategy against cancer. PLoS Pathog. 2014;10 doi: 10.1371/journal.ppat.1003836.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.ppat.1003836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parato K.A., Senger D., Forsyth P.A.J., Bell J.C. Recent progress in the battle between oncolytic viruses and tumours. Nat. Rev. Cancer. 2005;5:965–976. doi: 10.1038/nrc1750.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc1750</ArticleId>
            <ArticleId IdType="pubmed">16294217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lawler S.E., Speranza M.-C., Cho C.-F., Chiocca E.A. Oncolytic viruses in cancer treatment: a Review. JAMA Oncol. 2017;3:841. doi: 10.1001/jamaoncol.2016.2064.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2016.2064</ArticleId>
            <ArticleId IdType="pubmed">27441411</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pol J., Kroemer G., Galluzzi L. First oncolytic virus approved for melanoma immunotherapy. OncoImmunology. 2016;5 doi: 10.1080/2162402x.2015.1115641.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/2162402x.2015.1115641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rehman H., Silk A.W., Kane M.P., Kaufman H.L. Into the clinic: talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy. J. Immunother. Cancer. 2016;4:53. doi: 10.1186/s40425-016-0158-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-016-0158-5</ArticleId>
            <ArticleId IdType="pmc">PMC5029010</ArticleId>
            <ArticleId IdType="pubmed">27660707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Russell S.J., Peng K.-W., Bell J.C. Oncolytic virotherapy. Nat. Biotechnol. 2012;30:658–670. doi: 10.1038/nbt.2287.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nbt.2287</ArticleId>
            <ArticleId IdType="pmc">PMC3888062</ArticleId>
            <ArticleId IdType="pubmed">22781695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y.-P., Suksanpaisan L., Steele M.B., Russell S.J., Peng K.-W. Induction of antiviral genes by the tumor microenvironment confers resistance to virotherapy. Sci. Rep. 2013;3:2375. doi: 10.1038/srep02375.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep02375</ArticleId>
            <ArticleId IdType="pmc">PMC3736178</ArticleId>
            <ArticleId IdType="pubmed">23921465</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moerdyk-Schauwecker M., Shah N.R., Murphy A.M., Hastie E., Mukherjee P., Grdzelishvili V.Z. Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling. Virology. 2013;436:221–234. doi: 10.1016/j.virol.2012.11.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.virol.2012.11.014</ArticleId>
            <ArticleId IdType="pmc">PMC3544977</ArticleId>
            <ArticleId IdType="pubmed">23246628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diallo J.-S., Boeuf F.L., Lai F., Cox J., Vaha-Koskela M., Abdelbary H., MacTavish H., Waite K., Falls T., Wang J., et al.  A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers. Mol. Ther. 2010;18:1123–1129. doi: 10.1038/mt.2010.67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/mt.2010.67</ArticleId>
            <ArticleId IdType="pmc">PMC2889739</ArticleId>
            <ArticleId IdType="pubmed">20389287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Forbes N.E., Krishnan R., Diallo J.-S. Pharmacological modulation of anti-tumor immunity induced by oncolytic viruses. Front. Oncol. 2014;4:191. doi: 10.3389/fonc.2014.00191.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2014.00191</ArticleId>
            <ArticleId IdType="pmc">PMC4108035</ArticleId>
            <ArticleId IdType="pubmed">25101247</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dornan M.H., Krishnan R., Macklin A.M., Selman M., El Sayes N., Son H.H., Davis C., Chen A., Keillor K., Le P.J., et al.  First-in-class small molecule potentiators of cancer virotherapy. Sci. Rep. 2016;6:26786. doi: 10.1038/srep26786.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep26786</ArticleId>
            <ArticleId IdType="pmc">PMC4880900</ArticleId>
            <ArticleId IdType="pubmed">27226390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Phan M., Watson M.F., Alain T., Diallo J.-S. Oncolytic viruses on drugs: achieving higher therapeutic efficacy. ACS Infect. Dis. 2018;4:1448–1467. doi: 10.1021/acsinfecdis.8b00144.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsinfecdis.8b00144</ArticleId>
            <ArticleId IdType="pubmed">30152676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Selman M., Rousso C., Bergeron A., Son H.H., Krishnan R., El-Sayes N.A., Varette O., Chen A., Le Boeuf F., Tzelepis F., et al.  Multi-modal potentiation of oncolytic virotherapy by vanadium compounds. Mol. Ther. 2018;26:56–69. doi: 10.1016/j.ymthe.2017.10.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ymthe.2017.10.014</ArticleId>
            <ArticleId IdType="pmc">PMC5763159</ArticleId>
            <ArticleId IdType="pubmed">29175158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bergeron A., Kostenkova K., Selman M., Murakami H.A., Owens E., Haribabu N., Arulanandam R., Diallo J.-S., Crans D.C. Enhancement of oncolytic virotherapy by vanadium(V) dipicolinates. Biometals Int. J. Role Met. Ions Biol. Biochem. Med. 2019;32:545–561. doi: 10.1007/s10534-019-00200-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10534-019-00200-9</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McLauchlan C.C., Peters B.J., Willsky G.R., Crans D.C. Vanadium–phosphatase complexes: phosphatase inhibitors favor the trigonal bipyramidal transition state geometries. Coord. Chem. Rev. 2015;301–302:163–199. doi: 10.1016/j.ccr.2014.12.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2014.12.012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Irving Elsa, Stoker Andrew. Vanadium compounds as PTP inhibitors. Molecules. 2017;22:2269. doi: 10.3390/molecules22122269.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/molecules22122269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Evangelou A.M. Vanadium in cancer treatment. Crit. Rev. Oncol. Hematol. 2002;42:249–265. doi: 10.1016/s1040-8428(01)00221-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s1040-8428(01)00221-9</ArticleId>
            <ArticleId IdType="pubmed">12050018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia V., Krishnan R., Davis C., Batenchuk C., Le Boeuf F., Abdelbary H., Diallo J.-S. High-throughput titration of luciferase-expressing recombinant viruses. J. Vis. Exp. 2014:51890. doi: 10.3791/51890.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3791/51890</ArticleId>
            <ArticleId IdType="pmc">PMC4828131</ArticleId>
            <ArticleId IdType="pubmed">25285536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herbst R.S. Review of epidermal growth factor receptor biology. Int. J. Radiat. Oncol. 2004;59:S21–S26. doi: 10.1016/j.ijrobp.2003.11.041.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijrobp.2003.11.041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Platanias L.C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 2005;5:375–386. doi: 10.1038/nri1604.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri1604</ArticleId>
            <ArticleId IdType="pubmed">15864272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lupberger J., Duong F.H.T., Fofana I., Zona L., Xiao F., Thumann C., Durand S.C., Pessaux P., Zeisel M.B., Heim M.H., Baumert T.F. Epidermal growth factor receptor signaling impairs the antiviral activity of interferon-alpha: Hepatology. Hepatology. 2013;58:1225–1235. doi: 10.1002/hep.26404.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.26404</ArticleId>
            <ArticleId IdType="pubmed">23519785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quesnelle K.M., Boehm A.L., Grandis J.R. STAT-mediated EGFR signaling in cancer. J. Cell. Biochem. 2007;102:311–319. doi: 10.1002/jcb.21475.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcb.21475</ArticleId>
            <ArticleId IdType="pubmed">17661350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Essaghir A., Toffalini F., Knoops L., Kallin A., van Helden J., Demoulin J.-B. Transcription factor regulation can be accurately predicted from the presence of target gene signatures in microarray gene expression data. Nucleic Acids Res. 2010;38:e120. doi: 10.1093/nar/gkq149.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gkq149</ArticleId>
            <ArticleId IdType="pmc">PMC2887972</ArticleId>
            <ArticleId IdType="pubmed">20215436</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown K., Park S., Kanno T., Franzoso G., Siebenlist U. Mutual regulation of the transcriptional activator NF-kappa B and its inhibitor, I kappa B-alpha. Proc. Natl. Acad. Sci. 1993;90:2532–2536. doi: 10.1073/pnas.90.6.2532.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.90.6.2532</ArticleId>
            <ArticleId IdType="pmc">PMC46122</ArticleId>
            <ArticleId IdType="pubmed">8460169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beg A.A., Ruben S.M., Scheinman R.I., Haskill S., Rosen C.A., Baldwin A.S. I kappa B interacts with the nuclear localization sequences of the subunits of NF-kappa B: a mechanism for cytoplasmic retention. Genes Dev. 1992;6:1899–1913. doi: 10.1101/gad.6.10.1899.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.6.10.1899</ArticleId>
            <ArticleId IdType="pubmed">1340770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun L., Carpenter G. Epidermal growth factor activation of NF-κB is mediated through IκBα degradation and intracellular free calcium. Oncogene. 1998;16:2095–2102. doi: 10.1038/sj.onc.1201731.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.onc.1201731</ArticleId>
            <ArticleId IdType="pubmed">9572490</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shostak K., Chariot A. EGFR and NF-κB: partners in cancer. Trends Mol. Med. 2015;21:385–393. doi: 10.1016/j.molmed.2015.04.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molmed.2015.04.001</ArticleId>
            <ArticleId IdType="pubmed">25979753</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lawrence T. The nuclear factor NF- B pathway in inflammation. Cold Spring Harb. Perspect. Biol. 2009;1:a001651. doi: 10.1101/cshperspect.a001651.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/cshperspect.a001651</ArticleId>
            <ArticleId IdType="pmc">PMC2882124</ArticleId>
            <ArticleId IdType="pubmed">20457564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hiroi M., Ohmori Y. The transcriptional coactivator CREB-binding protein cooperates with STAT1 and NF-κB for synergistic transcriptional activation of the CXC ligand 9/Monokine induced by interferon-γ gene. J. Biol. Chem. 2003;278:651–660. doi: 10.1074/jbc.m204544200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.m204544200</ArticleId>
            <ArticleId IdType="pubmed">12403783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clarke D.L., Clifford R.L., Jindarat S., Proud D., Pang L., Belvisi M., Knox A.J. TNFα and IFNγ synergistically enhance transcriptional activation of CXCL10 in human airway smooth muscle cells via STAT-1, NF-κB, and the transcriptional coactivator CREB-binding protein. J. Biol. Chem. 2010;285:29101–29110. doi: 10.1074/jbc.m109.099952.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.m109.099952</ArticleId>
            <ArticleId IdType="pmc">PMC2937941</ArticleId>
            <ArticleId IdType="pubmed">20833730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McAusland T.M., van Vloten J.P., Santry L.A., Guilleman M.M., Rghei A.D., Ferreira E.M., Ingrao J.C., Arulanandam R., Major P.P., Susta L., et al.  Combining vanadyl sulfate with Newcastle disease virus potentiates rapid innate immune-mediated regression with curative potential in murine cancer models. Mol. Ther. - Oncolytics. 2021;20:306–324. doi: 10.1016/j.omto.2021.01.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.omto.2021.01.009</ArticleId>
            <ArticleId IdType="pmc">PMC7868934</ArticleId>
            <ArticleId IdType="pubmed">33614913</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoang H.-D., Graber T.E., Alain T. Battling for ribosomes: translational control at the forefront of the antiviral response. J. Mol. Biol. 2018;430:1965–1992. doi: 10.1016/j.jmb.2018.04.040.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jmb.2018.04.040</ArticleId>
            <ArticleId IdType="pubmed">29746850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thompson K.H., Orvig C. Vanadium in diabetes: 100 years from phase 0 to phase I. J. Inorg. Biochem. 2006;100:1925–1935. doi: 10.1016/j.jinorgbio.2006.08.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jinorgbio.2006.08.016</ArticleId>
            <ArticleId IdType="pubmed">17055061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rozzo C., Sanna D., Garribba E., Serra M., Cantara A., Palmieri G., Pisano M. Antitumoral effect of vanadium compounds in malignant melanoma cell lines. J. Inorg. Biochem. 2017;174:14–24. doi: 10.1016/j.jinorgbio.2017.05.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jinorgbio.2017.05.010</ArticleId>
            <ArticleId IdType="pubmed">28558258</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naso L.G., Badiola I., Marquez Clavijo J., Valcarcel M., Salado C., Ferrer E.G., Williams P.A.M. Inhibition of the metastatic progression of breast and colorectal cancer in vitro and in vivo in murine model by the oxidovanadium(IV) complex with luteolin. Bioorg. Med. Chem. 2016;24:6004–6011. doi: 10.1016/j.bmc.2016.09.058.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bmc.2016.09.058</ArticleId>
            <ArticleId IdType="pubmed">27707626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu Y., Ma Y., Xu Z., Wang D., Zhao B., Pan H., Wang J., Xu D., Zhao X., Pan S., et al.  Sodium orthovanadate inhibits growth of human hepatocellular carcinoma cells in vitro and in an orthotopic model in vivo. Cancer Lett. 2014;351:108–116. doi: 10.1016/j.canlet.2014.05.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2014.05.018</ArticleId>
            <ArticleId IdType="pubmed">24858025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bishayee A., Waghray A., Patel M.A., Chatterjee M. Vanadium in the detection, prevention and treatment of cancer: the in vivo evidence. Cancer Lett. 2010;294:1–12. doi: 10.1016/j.canlet.2010.01.030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2010.01.030</ArticleId>
            <ArticleId IdType="pubmed">20206439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim Y.-R., Cha H.-Y., Lim K., Hwang B.-D., Hoe K.-L., Namgung U., Park S.-K. Activation of epidermal growth factor receptor is responsible for pervanadate-induced phospholipase D activation. Exp. Mol. Med. 2003;35:118–124. doi: 10.1038/emm.2003.17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/emm.2003.17</ArticleId>
            <ArticleId IdType="pubmed">12754416</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lahusen T., Fereshteh M., Oh A., Wellstein A., Riegel A.T. Epidermal growth factor receptor tyrosine phosphorylation and signaling controlled by a nuclear receptor coactivator, amplified in breast cancer 1. Cancer Res. 2007;67:7256–7265. doi: 10.1158/0008-5472.can-07-1013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.can-07-1013</ArticleId>
            <ArticleId IdType="pmc">PMC3656436</ArticleId>
            <ArticleId IdType="pubmed">17671194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wieduwilt M.J., Moasser M.M. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell. Mol. Life Sci. 2008;65:1566–1584. doi: 10.1007/s00018-008-7440-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00018-008-7440-8</ArticleId>
            <ArticleId IdType="pmc">PMC3060045</ArticleId>
            <ArticleId IdType="pubmed">18259690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uchida H., Marzulli M., Nakano K., Goins W.F., Chan J., Hong C.-S., Mazzacurati L., Yoo J.Y., Haseley A., Nakashima H., et al.  Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus. Mol. Ther. 2013;21:561–569. doi: 10.1038/mt.2012.211.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/mt.2012.211</ArticleId>
            <ArticleId IdType="pmc">PMC3589172</ArticleId>
            <ArticleId IdType="pubmed">23070115</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piao Y., Jiang H., Alemany R., Krasnykh V., Marini F.C., Xu J., Alonso M.M., Conrad C.A., Aldape K.D., Gomez-Manzano C., Fueyo J. Oncolytic adenovirus retargeted to Delta-EGFR induces selective antiglioma activity. Cancer Gene Ther. 2009;16:256–265. doi: 10.1038/cgt.2008.75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cgt.2008.75</ArticleId>
            <ArticleId IdType="pmc">PMC3793894</ArticleId>
            <ArticleId IdType="pubmed">18927600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zaoui K., Bossow S., Grossardt C., Leber M.F., Springfeld C., Plinkert P.K., von Kalle C., Ungerechts G. Chemovirotherapy for head and neck squamous cell carcinoma with EGFR-targeted and CD/UPRT-armed oncolytic measles virus. Cancer Gene Ther. 2012;19:181–191. doi: 10.1038/cgt.2011.75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cgt.2011.75</ArticleId>
            <ArticleId IdType="pubmed">22076043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ueki I.F., Min-Oo G., Kalinowski A., Ballon-Landa E., Lanier L.L., Nadel J.A., Koff J.L. Respiratory virus–induced EGFR activation suppresses IRF1-dependent interferon λ and antiviral defense in airway epithelium. J. Exp. Med. 2013;210:1929–1936. doi: 10.1084/jem.20121401.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20121401</ArticleId>
            <ArticleId IdType="pmc">PMC3782052</ArticleId>
            <ArticleId IdType="pubmed">23999497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mitchell H.D., Eisfeld A.J., Stratton K.G., Heller N.C., Bramer L.M., Wen J., McDermott J.E., Gralinski L.E., Sims A.C., Le M.Q., et al.  The role of EGFR in influenza pathogenicity: multiple network-based approaches to identify a key regulator of non-lethal infections. Front. Cell Dev. Biol. 2019;7:200. doi: 10.3389/fcell.2019.00200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fcell.2019.00200</ArticleId>
            <ArticleId IdType="pmc">PMC6763731</ArticleId>
            <ArticleId IdType="pubmed">31616667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang L., Xu J., Guo L., Guo T., Zhang L., Feng L., Chen H., Wang Y. Porcine epidemic diarrhea virus-induced epidermal growth factor receptor activation impairs the antiviral activity of type I interferon. J. Virol. 2018;92 doi: 10.1128/jvi.02095-17. e02095–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/jvi.02095-17</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diao J., Pantua H., Ngu H., Komuves L., Diehl L., Schaefer G., Kapadia S.B. Hepatitis C virus induces epidermal growth factor receptor activation via CD81 binding for viral internalization and entry. J. Virol. 2012;86:10935–10949. doi: 10.1128/jvi.00750-12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/jvi.00750-12</ArticleId>
            <ArticleId IdType="pmc">PMC3457153</ArticleId>
            <ArticleId IdType="pubmed">22855500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beerli C., Yakimovich A., Kilcher S., Reynoso G.V., Fläschner G., Müller D.J., Hickman H.D., Mercer J. Vaccinia virus hijacks EGFR signalling to enhance virus spread through rapid and directed infected cell motility. Nat. Microbiol. 2019;4:216–225. doi: 10.1038/s41564-018-0288-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41564-018-0288-2</ArticleId>
            <ArticleId IdType="pmc">PMC6354922</ArticleId>
            <ArticleId IdType="pubmed">30420785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang C., Wang X., Veleeparambil M., Kessler P.M., Willard B., Chattopadhyay S., Sen G.C. EGFR-mediated tyrosine phosphorylation of STING determines its trafficking route and cellular innate immunity functions. EMBO J. 2020;39 doi: 10.15252/embj.2019104106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15252/embj.2019104106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lulli D., Carbone M.L., Pastore S. Epidermal growth factor receptor inhibitors trigger a type I interferon response in human skin. Oncotarget. 2016;7:47777–47793. doi: 10.18632/oncotarget.10013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.10013</ArticleId>
            <ArticleId IdType="pmc">PMC5216978</ArticleId>
            <ArticleId IdType="pubmed">27322144</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gong K., Guo G., Panchani N., Bender M.E., Gerber D.E., Minna J.D., Fattah F., Gao B., Peyton M., Kernstine K., et al.  EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer. Nat. Cancer. 2020;1:394–409. doi: 10.1038/s43018-020-0048-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s43018-020-0048-0</ArticleId>
            <ArticleId IdType="pmc">PMC7706867</ArticleId>
            <ArticleId IdType="pubmed">33269343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qureshi S.A., Leung S., Kerr I.M., Stark G.R., Darnell J.E. Function of Stat2 protein in transcriptional activation by alpha interferon. Mol. Cell. Biol. 1996;16:288–293. doi: 10.1128/mcb.16.1.288.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/mcb.16.1.288</ArticleId>
            <ArticleId IdType="pmc">PMC231002</ArticleId>
            <ArticleId IdType="pubmed">8524306</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blaszczyk K., Nowicka H., Kostyrko K., Antonczyk A., Wesoly J., Bluyssen H.A.R. The unique role of STAT2 in constitutive and IFN-induced transcription and antiviral responses. Cytokine Growth Factor Rev. 2016;29:71–81. doi: 10.1016/j.cytogfr.2016.02.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cytogfr.2016.02.010</ArticleId>
            <ArticleId IdType="pubmed">27053489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park C., Li S., Cha E., Schindler C. Immune response in Stat2 knockout mice. Immunity. 2000;13:795–804. doi: 10.1016/s1074-7613(00)00077-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s1074-7613(00)00077-7</ArticleId>
            <ArticleId IdType="pubmed">11163195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Christian S.L., Collier T.W., Zu D., Licursi M., Hough C.M., Hirasawa K. Activated Ras/MEK inhibits the antiviral response of alpha interferon by reducing STAT2 levels. J. Virol. 2009;83:6717–6726. doi: 10.1128/jvi.02213-08.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/jvi.02213-08</ArticleId>
            <ArticleId IdType="pmc">PMC2698556</ArticleId>
            <ArticleId IdType="pubmed">19386709</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noser J.A., Mael A.A., Sakuma R., Ohmine S., Marcato P., WK Lee P., Ikeda Y. The RAS/Raf1/MEK/ERK signaling pathway facilitates VSV-mediated oncolysis: implication for the defective interferon response in cancer cells. Mol. Ther. 2007;15:1531–1536. doi: 10.1038/sj.mt.6300193.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.mt.6300193</ArticleId>
            <ArticleId IdType="pubmed">17505473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han W., Carpenter R.L., Cao X., Lo H.-W. STAT1 gene expression is enhanced by nuclear EGFR and HER2 via cooperation with STAT3: STAT1 regulation BY nuclear EGFR and STAT3. Mol. Carcinog. 2013;52:959–969. doi: 10.1002/mc.21936.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mc.21936</ArticleId>
            <ArticleId IdType="pmc">PMC3482422</ArticleId>
            <ArticleId IdType="pubmed">22693070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andersen P., Pedersen M.W., Woetmann A., Villingshøj M., Stockhausen M.-T., Ødum N., Poulsen H.S. EGFR induces expression of IRF-1 via STAT1 and STAT3 activation leading to growth arrest of human cancer cells: EGFR Mediated IRF-1 Expression through STAT Activation. Int. J. Cancer. 2008;122:342–349. doi: 10.1002/ijc.23109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.23109</ArticleId>
            <ArticleId IdType="pubmed">17918184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng C., Lin H., Tsai K., Chiang Y., Lim K., Chen C.G., Su Y., Peng C., Ho A., Huang L., et al.  Epidermal growth factor induces STAT1 expression to exacerbate the IFNr-mediated PD-L1 axis in epidermal growth factor receptor-positive cancers. Mol. Carcinog. 2018;57:1588–1598. doi: 10.1002/mc.22881.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mc.22881</ArticleId>
            <ArticleId IdType="pubmed">30035369</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu T.R., Hong Y.K., Wang X.-D., Ling M.Y., Dragoi A.M., Chung A.S., Campbell A.G., Han Z.-Y., Feng G.-S., Chin Y.E. SHP-2 is a dual-specificity phosphatase involved in Stat1 dephosphorylation at both tyrosine and serine residues in nuclei. J. Biol. Chem. 2002;277:47572–47580. doi: 10.1074/jbc.m207536200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.m207536200</ArticleId>
            <ArticleId IdType="pubmed">12270932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang S., Zheng G., Zhao L., Xu F., Qian J. Shp-2 contributes to anti-RSV activity in human pulmonary alveolar epithelial cells by interfering with the IFN-α-induced Jak/Stat1 pathway. J. Cell. Mol. Med. 2015;19:2432–2440. doi: 10.1111/jcmm.12629.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jcmm.12629</ArticleId>
            <ArticleId IdType="pmc">PMC4594684</ArticleId>
            <ArticleId IdType="pubmed">26119280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Q., Pan W., Wang S., Pan C., Ning H., Huang S., Chiu S.-H., Chen J.-L. Protein tyrosine phosphatase SHP2 suppresses host innate immunity against influenza A virus by regulating EGFR-mediated signaling. J. Virol. 2021;95:e02001–e02020. doi: 10.1128/jvi.02001-20. /jvi/95/6/JVI.02001-20.atom.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/jvi.02001-20</ArticleId>
            <ArticleId IdType="pmc">PMC8094946</ArticleId>
            <ArticleId IdType="pubmed">33361428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Selman M., Ou P., Rousso C., Bergeron A., Krishnan R., Pikor L., Chen A., Keller B.A., Ilkow C., Bell J.C., Diallo J.S. Dimethyl fumarate potentiates oncolytic virotherapy through NF-κB inhibition. Sci. Transl. Med. 2018;10 doi: 10.1126/scitranslmed.aao1613.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aao1613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Du Z., Whitt M.A., Baumann J., Garner J.M., Morton C.L., Davidoff A.M., Pfeffer L.M. Inhibition of type I interferon-mediated antiviral action in human glioma cells by the IKK inhibitors BMS-345541 and TPCA-1. J. Interferon Cytokine Res. 2012;32:368–377. doi: 10.1089/jir.2012.0002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/jir.2012.0002</ArticleId>
            <ArticleId IdType="pmc">PMC3422054</ArticleId>
            <ArticleId IdType="pubmed">22509977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cataldi M., Shah N.R., Felt S.A., Grdzelishvili V.Z. Breaking resistance of pancreatic cancer cells to an attenuated vesicular stomatitis virus through a novel activity of IKK inhibitor TPCA-1. Virology. 2015;485:340–354. doi: 10.1016/j.virol.2015.08.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.virol.2015.08.003</ArticleId>
            <ArticleId IdType="pmc">PMC4619123</ArticleId>
            <ArticleId IdType="pubmed">26331681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ivashkiv L.B., Donlin L.T. Regulation of type I interferon responses. Nat. Rev. Immunol. 2014;14:36–49. doi: 10.1038/nri3581.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri3581</ArticleId>
            <ArticleId IdType="pmc">PMC4084561</ArticleId>
            <ArticleId IdType="pubmed">24362405</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohmori Y., Schreiber R.D., Hamilton T.A. Synergy between interferon-γ and tumor necrosis factor-α in transcriptional activation is mediated by cooperation between signal transducer and activator of transcription 1 and nuclear factor κB. J. Biol. Chem. 1997;272:14899–14907. doi: 10.1074/jbc.272.23.14899.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.272.23.14899</ArticleId>
            <ArticleId IdType="pubmed">9169460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shelton J.G., Steelman L.S., Abrams S.L., Bertrand F.E., Franklin R.A., McMahon M., McCubrey J.A. The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what’s genetics got to do with it? Expert Opin. Ther. Targets. 2005;9:1009–1030. doi: 10.1517/14728222.9.5.1009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1517/14728222.9.5.1009</ArticleId>
            <ArticleId IdType="pubmed">16185155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sigismund S., Avanzato D., Lanzetti L. Emerging functions of the EGFR in cancer. Mol. Oncol. 2018;12:3–20. doi: 10.1002/1878-0261.12155.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1878-0261.12155</ArticleId>
            <ArticleId IdType="pmc">PMC5748484</ArticleId>
            <ArticleId IdType="pubmed">29124875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jutten B., Keulers T.G., Schaaf M.B.E., Savelkouls K., Theys J., Span P.N., Vooijs M.A., Bussink J., Rouschop K.M.A. EGFR overexpressing cells and tumors are dependent on autophagy for growth and survival. Radiother. Oncol. 2013;108:479–483. doi: 10.1016/j.radonc.2013.06.033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.radonc.2013.06.033</ArticleId>
            <ArticleId IdType="pubmed">23891088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liccardi G., Hartley J.A., Hochhauser D. EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment. Cancer Res. 2011;71:1103–1114. doi: 10.1158/0008-5472.can-10-2384.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.can-10-2384</ArticleId>
            <ArticleId IdType="pmc">PMC3033323</ArticleId>
            <ArticleId IdType="pubmed">21266349</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tao Y., Song X., Deng X., Xie D., Lee L.M., Liu Y., Li W., Li L., Deng L., Wu Q., et al.  Nuclear accumulation of epidermal growth factor receptor and acceleration of G1/S stage by Epstein–Barr-encoded oncoprotein latent membrane protein 1. Exp. Cell Res. 2005;303:240–251. doi: 10.1016/j.yexcr.2004.09.030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.yexcr.2004.09.030</ArticleId>
            <ArticleId IdType="pubmed">15652339</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arulanandam R., Batenchuk C., Angarita F.A., Ottolino-Perry K., Cousineau S., Mottashed A., Burgess E., Falls T.J., De Silva N., Tsang J., et al.  VEGF-mediated induction of PRD1-BF1/Blimp1 expression sensitizes tumor vasculature to oncolytic virus infection. Cancer Cell. 2015;28:210–224. doi: 10.1016/j.ccell.2015.06.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2015.06.009</ArticleId>
            <ArticleId IdType="pubmed">26212250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stojdl D.F., Lichty B.D., tenOever B.R., Paterson J.M., Power A.T., Knowles S., Marius R., Reynard J., Poliquin L., Atkins H., et al.  VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell. 2003;4:263–275. doi: 10.1016/s1535-6108(03)00241-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s1535-6108(03)00241-1</ArticleId>
            <ArticleId IdType="pubmed">14585354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diallo J.-S., Vähä-Koskela M., Le Boeuf F., Bell J.  In: Oncolytic Viruses Methods in Molecular Biology. Kirn D.H., Liu T.-C., Thorne S.H., editors. Humana Press; 2012. Propagation, purification, and in vivo testing of oncolytic vesicular stomatitis virus strains; pp. 127–140.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
